XML 48 R29.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Segment and Geographic Information | 12 Months Ended
--- | ---
Apr. 28, 2017
Segment Reporting [Abstract] |
Segment and Geographic Information | Segment and Geographic Information The Company’s management evaluates performance and allocates resources based on income before interest expense, net, the provision for income taxes and amortization of intangible assets, not including centralized distribution costs and corporate charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in Note 1. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during fiscal year 2017. As a result, the Company has revised the disclosure for prior periods to align with current presentation. The Company’s Cardiac and Vascular Group consists of three divisions: Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral Vascular. The primary products sold by this operating segment include products for cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart and vascular-related disorders and diseases. The products produced by this operating segment require highly-skilled, technical manufacturing processes and are distributed through direct sales representatives in the U.S. and through direct sales representatives and indirect distributors outside of the U.S. Further, the primary customers of this operating segment are surgeons and specialists and the regulatory approval process for the Cardiac and Vascular Group is similar across all divisions. The Company’s Minimally Invasive Therapies Group consists of two divisions: Surgical Solutions and Patient Monitoring & Recovery. The primary products sold by this operating segment include those which enhance patient outcomes through minimally invasive solutions. These products include those for advanced and general surgical care and patient monitoring, patient care, renal care, and airway and ventilation. Further, the regulatory approval process for the Minimally Invasive Therapies Group is similar across all divisions. In the first quarter of fiscal year 2017, the Company realigned the divisions within the Restorative Therapies Group. The Company’s Restorative Therapies Group consists of four divisions: Spine, Brain Therapies, Specialty Therapies, and Pain Therapies. The primary customers of this operating segment include spinal surgeons, neurosurgeons, and pain specialists. The products sold by this operating segment are distributed through direct sales representatives in the U.S. and through direct sales representatives and indirect distributors outside of the U.S. Further, the regulatory approval process for the Restorative Therapies Group is similar across all divisions. The primary products sold by the Company’s Diabetes Group include those for diabetes management, and the regulatory approval process for the Diabetes Group is similar across all divisions. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Segment disclosures are on a performance basis consistent with internal management reporting. Certain items are at corporate and centralized and are not allocated to the segments. Net sales and earnings before other adjustments by reportable segment are as follows:
| Fiscal Year
(in millions) | 2017 |  | 2016 |  | 2015
Cardiac and Vascular Group | $ | 10,498 |  |  | $ | 10,196 |  |  | $ | 9,361 |
Minimally Invasive Therapies Group | 9,919 |  |  | 9,563 |  |  | 2,387 |
Restorative Therapies Group | 7,366 |  |  | 7,210 |  |  | 6,751 |
Diabetes Group | 1,927 |  |  | 1,864 |  |  | 1,762 |
Total | $ | 29,710 |  |  | $ | 28,833 |  |  | $ | 20,261 |
| Fiscal Year
(in millions) | 2017 |  | 2016 |  | 2015
Cardiac and Vascular Group | $ | 4,134 |  |  | $ | 3,986 |  |  | $ | 3,836 |
Minimally Invasive Therapies Group | 3,434 |  |  | 3,373 |  |  | 775 |
Restorative Therapies Group | 2,868 |  |  | 2,671 |  |  | 2,445 |
Diabetes Group | 690 |  |  | 667 |  |  | 663 |
Reportable segments' EBITA before other adjustments(1) | 11,126 |  |  | 10,697 |  |  | 7,719 |
Impact of inventory step-up | (38 | ) |  | (226 | ) |  | (623 | )
Impact of product technology upgrade commitment | — |  |  | — |  |  | (74 | )
Special charge (gain), net | (100 | ) |  | (70 | ) |  | 38 |
Restructuring charges, net (2) | (373 | ) |  | (299 | ) |  | (252 | )
Certain litigation charges | (300 | ) |  | (26 | ) |  | (42 | )
Acquisition-related items (2) | (230 | ) |  | (283 | ) |  | (550 | )
Amortization of intangible assets | (1,980 | ) |  | (1,931 | ) |  | (733 | )
Centralized distribution costs | (1,543 | ) |  | (1,177 | ) |  | (794 | )
Interest expense, net | (728 | ) |  | (955 | ) |  | (280 | )
Corporate | (1,232 | ) |  | (1,394 | ) |  | (923 | )
Income before provision for income taxes | $ | 4,602 |  |  | $ | 4,336 |  |  | $ | 3,486 |
(1) | Represents earnings by segment before interest expense, net, amortization of intangible assets, corporate charges, and centralized distribution costs.
(2) | Restructuring charges, net and acquisition-related items within this table include the impact of amounts recognized within cost of products sold in the consolidated statements of income.
The following table presents the Company’s assets by reportable segment:
(in millions) | April 28, 2017 |  | April 29, 2016
Cardiac and Vascular Group | $ | 15,192 |  |  | $ | 13,563 |
Minimally Invasive Therapies Group(1) | 49,249 |  |  | 52,227 |
Restorative Therapies Group | 15,441 |  |  | 14,564 |
Diabetes Group | 2,641 |  |  | 2,592 |
Total assets of reportable segments | 82,523 |  |  | 82,946 |
Corporate | 17,293 |  |  | 16,698 |
Total Assets | $ | 99,816 |  |  | $ | 99,644 |
(1) | Assets of $6.3 billion classified as held for sale were included within Minimally Invasive Therapies Group at April 28, 2017.
Geographic Information The following table presents net sales to external customers and property, plant, and equipment, net by geographic region:
| Net sales to external customers |  | Property, plant, and equipment, net
(in millions) | 2017 |  | 2016 |  | 2015 |  | April 28, 2017 |  | April 29, 2016
Americas(1) | $ | 17,939 |  |  | $ | 17,578 |  |  | $ | 12,125 |  |  | $ | 3,270 |  |  | $ | 3,728 |
EMEA(2) | 6,739 |  |  | 6,700 |  |  | 5,064 |  |  | 709 |  |  | 708 |
Asia Pacific | 3,443 |  |  | 3,060 |  |  | 2,059 |  |  | 192 |  |  | 220 |
Greater China | 1,589 |  |  | 1,495 |  |  | 1,013 |  |  | 190 |  |  | 185 |
Consolidated | $ | 29,710 |  |  | $ | 28,833 |  |  | $ | 20,261 |  |  | $ | 4,361 |  |  | $ | 4,841 |
(1) | The U.S., which is included in the Americas, had net sales to external customers of $16.7 billion, $16.4 billion, and $11.3 billion in fiscal years 2017, 2016, and 2015, respectively. Property, plant, and equipment, net includes $2.5 billion and $3.3 billion in the U.S. in fiscal years 2017 and 2016, respectively.
(2) | EMEA consists of the following regions: Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented. Property, plant, and equipment, net includes $171 million and $169 million in Ireland in fiscal years 2017 and 2016, respectively.
No single customer represented over 10 percent of the Company’s consolidated net sales in fiscal years 2017, 2016, or 2015.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration